The goal of this clinical trial is to learn whether an artificial intelligence-enhanced electrocardiogram (AI-ECG) strategy improves timely intervention of patients requiring cardiac implantable electronic devices (CIEDs), compared with standard clinical care.
At least one 12-lead ECG within 1 year
Diagnosis of sick sinus syndrome
Diagnosis of high-grade or complete atrioventricular block
Diagnosis of ventricular tachycardia or ventricular fibrillation
Post CIED implant
Parallel
AI-ECG driven ECG monitoring
Diagnostic testParticipants identified as high-risk for CIED implantation by the AI-ECG system will receive a continuous cardiac rhythm monitor for up to 7 days.
CIED implantation
The number of participants who undergo CIED implantation within the study period. The CIEDs include conventional transvenous pacemakers, leadless pacemakers, and implantable cardioverter-defibrillators (encompassing transvenous, subcutaneous, and extravascular systems).
Number of High-Grade Atrioventricular Block
Number of Complete Atrioventricular Block
Number of Sick Sinus Syndrome
Number of Ventricular Arrhythmia
Click on the lead sponsor to view all of their trials.
